Form 4: Azitra CEO Acquires Significant Convertible Securities

Azitra's President and CEO, Francisco D. Salva, acquired Series A Preferred Stock and Series B and C Warrants, contingent on future stockholder approvals and study results.

Summary

• Francisco D. Salva, Azitra's President and CEO, Director, and 10% Owner, acquired 500 shares of Series A Convertible Non-Redeemable Preferred Stock on March 18, 2026.
• Each share of Series A Preferred Stock has a stated value of $1,000 and automatically converts into 8,128.1 shares of Common Stock, subject to adjustment.
• Conversion of Series A Preferred Stock is contingent upon stockholder approval to increase authorized common stock and approve the conversion itself, as well as filing an amendment to the Certificate of Incorporation.
• Salva also acquired 4,064,050 Series B Warrants and 4,064,050 Series C Warrants on March 18, 2026, both with an exercise price of $0.123.
• Series B Warrants are exercisable upon stockholder approval and will terminate 18 months following such approval.
• Series C Warrants are exercisable upon stockholder approval and will terminate, with certain exceptions, 30 calendar days after Azitra publicly announces data from its planned human cosmetic study testing the filaggrin technology.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive signal, given the significant insider purchase by the CEO, Director, and 10% owner, indicating high confidence in the company's future and its strategic direction, despite the contingencies.

Positives

• The acquisition of significant convertible preferred stock and warrants by the President and CEO, Director, and 10% Owner signals strong insider confidence in Azitra's future prospects.
• The potential conversion of Series A Preferred Stock and exercise of Series B and C Warrants could significantly increase the CEO's direct ownership in the company's common stock.

Negatives

• The conversion of Series A Preferred Stock and exercisability of Series B and C Warrants are contingent on future stockholder approvals, introducing a degree of uncertainty.
• The termination clauses for Series B and C Warrants (18 months post-approval and 30 days post-study data announcement, respectively) create a time-sensitive window for their value realization.

Risks

• Failure to obtain stockholder approval for increasing authorized common stock or for the conversion of Series A Preferred Stock could prevent the conversion of these securities.
• The value of the warrants is dependent on the future stock price of Azitra, Inc. exceeding the exercise price of $0.123.
• The Series C Warrants' termination is tied to the announcement of data from a human cosmetic study, introducing risk related to study outcomes and timing.

Future Outlook

The future conversion of Series A Preferred Stock and exercisability of Series B and C Warrants are dependent on obtaining stockholder approval for increasing authorized common stock and for the conversion itself. Additionally, the Series C Warrants' termination is linked to the public announcement of data from Azitra's planned human cosmetic study testing its filaggrin technology.

Industry Context

StockSavvy.ai notes that insider purchases, especially by top executives and significant shareholders, are often viewed positively by the market as they indicate management's belief in the company's undervaluation or strong future prospects. For a biotechnology company like Azitra, the success of its planned human cosmetic study is a critical milestone, and the CEO's investment tied to this outcome suggests confidence in the research pipeline.

Comparison to Industry Standards

• Insider buying activity, particularly by a CEO and 10% owner, is generally considered a strong signal of confidence, often outperforming general market sentiment. For example, studies by academic institutions like the University of Pennsylvania's Wharton School have shown that portfolios mimicking insider buying tend to generate alpha.
• The structure of convertible preferred stock and warrants is a common financing mechanism for early-stage biotechnology companies, allowing for capital infusion while deferring full dilution until certain milestones (like stockholder approval or clinical data) are met. This is comparable to similar financing rounds seen in emerging biotech firms like those funded by venture capital or private equity before or during public listing.

Corporate Governance

Related Party Transactions

• The transaction involves Francisco D. Salva, who is the President and CEO, a Director, and a 10% owner of Azitra, Inc., making it a related party transaction.

Stakeholder Impact

• Shareholders: Potential for future dilution upon conversion of preferred stock and exercise of warrants, but also a strong signal of insider confidence.
• Management: The CEO's increased stake aligns his interests more closely with long-term shareholder value.
• Company: The issuance of these securities likely provided capital to the company, supporting its operations and research initiatives.

Next Steps

• Azitra's stockholders need to approve an increase in the number of authorized shares of Common Stock.
• Azitra's stockholders need to approve the conversion of Series A Preferred Stock into Common Stock.
• Azitra needs to file an amendment to its Certificate of Incorporation with the Secretary of State of Delaware evidencing stockholder approval.
• Azitra plans to publicly announce data from its human cosmetic study testing the filaggrin technology.

Key Dates

Recommendation

The significant acquisition of convertible preferred stock and warrants by Azitra's CEO, who is also a Director and 10% owner, is a strong indicator of insider confidence. This type of insider buying often precedes positive company developments and suggests management believes the stock is undervalued. While contingencies exist, the CEO's willingness to tie a substantial investment to future milestones, including a key cosmetic study, provides a compelling reason for a 'buy' recommendation for investors seeking growth potential in the biotechnology sector.

Keywords

Azitra Inc., AZTR, Form 4, Insider Trading, Convertible Preferred Stock, Warrants, Francisco D. Salva, Corporate Governance, Stockholder Approval, Biotechnology, Dermatology, Filaggrin Technology